GB1533464A - Cancer diagnostic agents - Google Patents

Cancer diagnostic agents

Info

Publication number
GB1533464A
GB1533464A GB6357/76A GB635776A GB1533464A GB 1533464 A GB1533464 A GB 1533464A GB 6357/76 A GB6357/76 A GB 6357/76A GB 635776 A GB635776 A GB 635776A GB 1533464 A GB1533464 A GB 1533464A
Authority
GB
United Kingdom
Prior art keywords
recognin
dissolved
solubilised
tissue
recognins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB6357/76A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of GB1533464A publication Critical patent/GB1533464A/en
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4731Recognins, e.g. malignin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5748Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

In the process for the preparation of recognins, optionally provided with a carrier, normal or diseased tissue is extracted with a neutral buffer with repeated disintegration of the tissue. By this means, protein fractions are dissolved or solubilised. Extraction is then carried out. The fraction having a pK range of 1 to 4 is separated off from the resulting extract of the dissolved or solubilised proteins. This is achieved by adding the extract of the dissolved or solubilised proteins to a chromatographic column and eluting with increasingly acidic solvents. A product is isolated therefrom having a molecular weight of 3,000 to 25,000. The isolation is carried out by filtering the eluate in order to obtain a fraction which contains recognin. The recognin is separated therefrom by thin-layer gel chromatography. The recognin obtained is optionally mixed with a carrier for the purpose of forming a complex compound. This process enables the preparation of recognins which are used for diagnosis and for control of malignant tissue.
GB6357/76A 1975-02-18 1975-10-15 Cancer diagnostic agents Expired GB1533464A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55043275A 1975-02-18 1975-02-18
US55307575A 1975-02-25 1975-02-25
US62111275A 1975-10-09 1975-10-09

Publications (1)

Publication Number Publication Date
GB1533464A true GB1533464A (en) 1978-11-22

Family

ID=27415588

Family Applications (1)

Application Number Title Priority Date Filing Date
GB6357/76A Expired GB1533464A (en) 1975-02-18 1975-10-15 Cancer diagnostic agents

Country Status (4)

Country Link
JP (2) JPH0146520B2 (en)
CH (1) CH639102A5 (en)
DE (1) DE2606257A1 (en)
GB (1) GB1533464A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0015755A2 (en) * 1979-03-09 1980-09-17 Samuel Dr. Bogoch Recognins, their chemoreciprocals, target attaching globulins and processes for producing these products; methods of detecting cancer tumors

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0007214B1 (en) * 1978-07-07 1985-10-23 Samuel Dr. Bogoch Product for detecting the presence of cancerous or malignant tumor cells
CH645728A5 (en) * 1979-01-30 1984-10-15 Otsuka Pharma Co Ltd PROCESS FOR DETERMINING THE CONTENT OF SUBSTANCES CONTAINING GLUCOSIDIC BONDS ASSOCIATED WITH TUMORS, APPLICATION OF THIS PROCESS AND NECESSARY FOR ITS IMPLEMENTATION.

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0015755A2 (en) * 1979-03-09 1980-09-17 Samuel Dr. Bogoch Recognins, their chemoreciprocals, target attaching globulins and processes for producing these products; methods of detecting cancer tumors
EP0015755A3 (en) * 1979-03-09 1980-12-10 Samuel Dr. Bogoch Recognins, their chemoreciprocals, target attaching globulins and processes for producing these products; methods of detecting cancer tumors

Also Published As

Publication number Publication date
DE2606257A1 (en) 1976-08-26
JPH0257671B2 (en) 1990-12-05
JPS51108001A (en) 1976-09-25
CH639102A5 (en) 1983-10-31
JPH0146520B2 (en) 1989-10-09
JPH01112163A (en) 1989-04-28

Similar Documents

Publication Publication Date Title
YU41776A (en) Process for obtaining protein concentrates suitable as foodstuffs by separation of phenol and oligosaccharides from vegetable tissues
NL7612673A (en) PROCESS FOR THE PREPARATION OF PHARMACEUTICAL PREPARATIONS AS AVAILABLE FOR THE TREATMENT OF CALCIUM SUBSTANCE INTERFERENCES.
Swager et al. Coumarins from Musineon divaricatum
Kessel et al. Purification and analysis of hematoporphyrin and hematoporphyrin derivative by gel exclusion and reverse‐phase chromatography
GB1533464A (en) Cancer diagnostic agents
EP0216936A4 (en) Novel tannin composition.
NL7606612A (en) PROCESS FOR THE PREPARATION OF NEW PHARMACEUTICAL PREPARATIONS.
Herring et al. The isolation of soluble proteins, glycoproteins, and proteoglycans from bone
NL188948B (en) PROCESS FOR THE PREPARATION OF PYRIDO (1,2A) PYRIMIDINES, ANTI-INFLAMMATION AND BLOOD CLOTTING PROCESS, AND PROCESS FOR THE PREPARATION OF PHARMACEUTICAL PREPARATIONS CONTAINING THESE.
NL7711916A (en) PROCESS FOR PREPARING HIGHLY CONCENTRATED PHARMACEUTICAL PREPARATIONS OF STEROIDS.
Okudaira et al. Cytotoxic factor demonstrated in lymph node extract
Lunde Location of lipid‐soluble selenium in marine fish to the lipoproteins
ES437046A2 (en) Manufacture of novel amino acid derivative
Peralta et al. (-)-epicatechin-3-galloyl ester: a secretagogue compound from the bark of Sclerocarya birrea
GB1430885A (en) Process for preparing a purified extract of quillaia bark
Miccio et al. Bilitranslocase is the protein responsible for the electrogenic movement of sulfobromophthalein in plasma membrane vesicles from rat liver: immunochemical evidence using mono-and poly-clonal antibodies
Dickinson et al. The chemical nature of cancer basic protein
Axelsson et al. Identification of bufotenin in toad brain by chromatography and mass spectrometry of its dans-derivative
ES447851A1 (en) Process for the extraction of components having anticoagulant activity {37 in vivo{38 {0 from snake venoms and products obtained
OHASHI et al. Purification of toxohormone by DEAE-cellulose columnchromatography
ES388011A1 (en) Process for the production of pigmented coating powders
NL7607693A (en) PROCESS FOR THE PREPARATION OF ANTI-BLOOD-PRESSURE-ACTING PREPARATIONS.
Helmy et al. An ethanolamine plasmalogen artifact formed by acetone extraction of freeze-dried tissue
DE2967143D1 (en) Diagnostic method, especially for the early recognition of malignant tumors and/or viral diseases, and means to carry it out
GB1443053A (en) Cancer associated polypeptide antigen process for its pre paration and composition useful as an immunizing agent

Legal Events

Date Code Title Description
PS Patent sealed
PCNP Patent ceased through non-payment of renewal fee
728C Application made for restoration (sect. 28/1977)
728A Order made restoring the patent (sect. 28/1977)
PCNP Patent ceased through non-payment of renewal fee